Microdose Psychedelic Insights, a cutting-edge media company focused on promoting content, financial analysis, and engaging events designed to drive the psychedelics industry into the forefront of modern medicine, will be hosting next month’s DMT Conference. Held in an entirely virtual format, the conference is slated for Sept. 9–10, 2021. According to the announcement, the event will focus on the potential of dimethyltryptamine (“DMT”) regarding drug development and safety, clinical care, law and regulation, business and markets, science and research. The DMT conference is part of Microdose’s Molecular Masterclasses conference events, a speaker series designed for deep dives into the world’s favorite psychoactive and psychedelic substances. The informative DMT Conference is designed to provide insight and education into the space of DMT therapeutics and will feature expert panels and engaging discussions. The 2021 conference will feature a presentation by CEO of Microdose Psychedelic Insights Patrick Moher as well as a series of hourlong presentations and various keynote addresses. Topics to be covered will include “Addiction and DMT,” “Non-Neuropsychiatric Uses for DMT,” “DMT Drug Development,” and a keynote presentation by Algernon Pharmaceuticals titled “DMT — New Hope for Healing the Brain After a Stroke,” among others. Conference presenters include Christopher Timmermann-Slater, Andrew Hegle, Paul Van Slyke, Daniel Cohen, Christopher Moreau, Jackie von Salm, Carol Routledge, Brian Jahns, Natan Ponieman, Andrew Hegle Paul Van Slyke, Peter Rands, Graham Pechenik, David Wood, Ruth Chun, Hadas Alterman, Rick Strassman, Timothy Ko, Brian Jahns, Crystal Carson, Joël Brierre, Max Montrose, Tricia Eastman, Rak Razam, and Victoria Wueschner among others.
To attend the full conference, visit https://ibn.fm/7TbOg
To view the full press release, visit https://ibn.fm/ellGA
About Microdose Psychedelic Insights
Microdose Psychedelic Insights is a guide to the psychedelic medicine industry. With a vision to shift the world’s perception of psychedelic medicine, the company distribute and create the most compelling content, financial analysis, engaging events, and ground-breaking education to drive the psychedelics industry to the forefront of modern medicine. For more information about the company, visit www.Microdose.buzz.
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.investorwire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork.